

Bal Pharma Limited

To, The Manager-Listing National Stock Exchange of India Ltd Mumbai.

28.05.2024

BSE Limited Mumbai.

Dear Sir,

Sub : Outcome of the Board Meeting. Ref : Regulation 33 of SEBI(LODR) Regulations,2015.

The Board of Directors of the Company has met today and *inter alia* transacted the following business.

1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2024. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges.

2.Recommended dividend of Re.1.20/- per equity share of Rs.10/- each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.

3.Appointed Murugesh & Co, Chartered Accountants as Internal Auditors, Mr.M.R Krishna Murthy, Cost Accountants as Cost Auditors and Mr.Prameshwar G. Bhat , Practicing Company Secretary as Secretarial Auditors of the Company for the financial year 2024-25.

The meeting commenced at 4.30 p.m and concluded at 5.45 p.m on 28.05.2024.

Please take this intimation on record.

For Bal Pharma Limited

Shailesh Siroya **Managing Director** CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India Ph.: 91 - 80 - 41379500 Fax: 91 - 80 - 22354057 / 58 Email : info@balpharma.com Website : www.balpharma.com CIN # L85110KA1987PLC008368 REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Ph. :080-41570811 / 13 / 19 Fax : 41570820